Prescott Group Capital Management L.L.C. Buys Shares of 180,525 ClearPoint Neuro, Inc. $CLPT

Posted by on May 21st, 2026

Prescott Group Capital Management L.L.C. bought a new stake in ClearPoint Neuro, Inc. (NASDAQ:CLPT – Free Report) during the 4th quarter, Holdings Channel.com reports. The firm bought 180,525 shares of the company’s stock, valued at approximately $2,470,000.

Other institutional investors have also recently bought and sold shares of the company. Huntington National Bank bought a new stake in shares of ClearPoint Neuro during the 3rd quarter worth approximately $44,000. BNP Paribas Financial Markets boosted its holdings in shares of ClearPoint Neuro by 2,435.2% in the 2nd quarter. BNP Paribas Financial Markets now owns 2,231 shares of the company’s stock valued at $27,000 after buying an additional 2,143 shares during the last quarter. Russell Investments Group Ltd. boosted its holdings in shares of ClearPoint Neuro by 1,079.0% in the 3rd quarter. Russell Investments Group Ltd. now owns 2,358 shares of the company’s stock valued at $51,000 after buying an additional 2,158 shares during the last quarter. Legal & General Group Plc acquired a new stake in shares of ClearPoint Neuro in the 2nd quarter valued at approximately $35,000. Finally, Osaic Holdings Inc. boosted its holdings in shares of ClearPoint Neuro by 119.8% in the 2nd quarter. Osaic Holdings Inc. now owns 7,705 shares of the company’s stock valued at $92,000 after buying an additional 4,200 shares during the last quarter. Institutional investors own 30.08% of the company’s stock.

ClearPoint Neuro Stock Performance

Shares of NASDAQ CLPT opened at $11.20 on Thursday. The company has a debt-to-equity ratio of 2.63, a current ratio of 5.79 and a quick ratio of 4.88. The stock’s fifty day moving average price is $10.55 and its two-hundred day moving average price is $12.88. ClearPoint Neuro, Inc. has a one year low of $8.27 and a one year high of $30.10. The firm has a market cap of $335.89 million, a price-to-earnings ratio of -11.09 and a beta of 1.29.

ClearPoint Neuro (NASDAQ:CLPT – Get Free Report) last issued its quarterly earnings data on Wednesday, May 13th. The company reported ($0.32) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.04). ClearPoint Neuro had a negative net margin of 71.57% and a negative return on equity of 140.96%. The firm had revenue of $12.13 million during the quarter, compared to analyst estimates of $11.97 million. On average, equities analysts forecast that ClearPoint Neuro, Inc. will post -1.05 EPS for the current year.

Wall Street Analyst Weigh In

CLPT has been the subject of several recent analyst reports. Stifel Nicolaus initiated coverage on ClearPoint Neuro in a report on Friday, May 8th. They issued a “buy” rating and a $16.00 price objective for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of ClearPoint Neuro in a report on Monday, April 20th. Finally, B. Riley Financial increased their price objective on ClearPoint Neuro from $18.00 to $20.00 and gave the company a “buy” rating in a report on Wednesday, March 18th. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, ClearPoint Neuro currently has an average rating of “Hold” and an average price target of $18.00.

Get Our Latest Report on ClearPoint Neuro

ClearPoint Neuro Profile

(Free Report)

ClearPoint Neuro, Inc is a medical technology company specializing in the development and commercialization of an MRI-guided therapy platform for minimally invasive neurosurgical procedures. Headquartered in Cambridge, Massachusetts, the company’s flagship ClearPoint® SmartFrame™ system enables surgeons to perform accurate and efficient intracranial interventions by providing real-time magnetic resonance imaging feedback. This technology is designed to improve patient safety and outcomes in treatments ranging from deep brain stimulation electrode placement to laser ablation of epileptic foci and brain tumors.

The ClearPoint System integrates hardware, software and imaging capabilities to guide instruments through the brain with submillimeter precision.

Featured Stories

Want to see what other hedge funds are holding CLPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ClearPoint Neuro, Inc. (NASDAQ:CLPT – Free Report).

Institutional Ownership by Quarter for ClearPoint Neuro (NASDAQ:CLPT)

Receive News & Ratings for ClearPoint Neuro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ClearPoint Neuro and related companies with MarketBeat.com's FREE daily email newsletter.